-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source: Guanlan Pharmaceutical
Recently, Arnold Pharma announced that its original innovative drug, the oral PD-L1 inhibitor AN4005, has been approved by the National Medical Products Administration (NMPA) for drug clinical trials.
AN4005 is a specific orally active PD-L1 antagonist developed by Arnold Pharma
In preclinical studies, AN4005 has shown good anti-tumor activity